Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow
unchecked when an oncogneic signal is present. Obatoclax is designed to restore apoptosis
through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process
of cell death that is often inhibited in cancer cells.